2001, Number 3
Effect over ten days of treatment with the combination loratadine/ambroxol in pediatric solution, on the clinical allergic rhinitis symptoms associated to cough, in a 6-12 years old pediatric patients
Fregoso OA, Orozco MS
Full text
Language: Spanish
References: 9
Page: 93-103
PDF size: 464.37 Kb.
ABSTRACT
This clinical study was designed to determine the efficacy and safety of a new combination loratadine 1.0 mg/mL/ambroxol 6.0 mg/mL in pediatric solution, taken twice a day (every 12 hours), in comparison with it is own separated components, loratadine and ambroxol, during ten days. This study was developed in the pediatric service of the Hospital Escandón in Mexico City. It was done as a double blind, randomized, prospective and comparative study, over 6 months, with an inclusion of 123 pediatric patients between 6 to 12 years of age, who had allergic rhinitis associated with cough. To determine the efficacy of each treatment, it was evaluated the clinical evolution of the following parameters: Sneezes, rhinorrhea, lacrimation, nasal pruritus, cough and it is predominance during day or night, retronasal discharge, nasal congestion and total clinical signs. Additionally, the investigator and all patients made an evaluation of the clinical response. The results demonstrated that the combination loratadine/ambroxol was more effective in all clinical parameters in comparison with it is own separated components, and they were expressed in a notorious and progressive way between the fifth and tenth day of treatment, confirming that loratadine, besides of it is immediate effect on H1 receptors, has antiinflammatory effects that progress during the ten days, reason to propose that treatments indicated for acute episode of allergic rhinitis should have a duration of ten or more days.REFERENCES